Search

Your search keyword '"van der Velden, Walter J.F.M."' showing total 26 results
Start Over Author "van der Velden, Walter J.F.M." Publication Type Academic Journals
26 results on '"van der Velden, Walter J.F.M."'

2. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

Author

Rijneveld, Anita W., van der Holt, Bronno, de Weerdt, Okke, Biemond, Bart J., van de Loosdrecht, Arjen A., van der Wagen, Lotte E., Bellido, Mar, van Gelder, Michel, van der Velden, Walter J.F.M., Selleslag, Dominik, van Lammeren-Venema, Daniëlle, Halkes, Constantijn J.M., Fijnheer, Rob, Havelange, Violaine, van Sluis, Geerte L., Legdeur, Marie-Cecile, Deeren, Dries, Gadisseur, Alain, Sinnige, Harm A.M., Breems, Dimitri A., Jaspers, Aurélie, Legrand, Ollivier, Terpstra, Wim E., Boersma, Rinske S., Mazure, Dominiek, Triffet, Agnes, Tick, Lidwine W., Beel, Karolien, Maertens, Johan A., Beverloo, H. Berna, Bakkus, Marleen, Homburg, Christa H.E., de Haas, Valerie, van der Velden, Vincent H.J., and Cornelissen, Jan J.

Published
2022
Full Text
View/download PDF

4. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

5. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation

Author

Sommer, Sebastian, Cruijsen, Marjan, Claus, Rainer, Bertz, Hartmut, Wäsch, Ralph, Marks, Reinhard, Zeiser, Robert, Bogatyreva, Lioudmila, Blijlevens, Nicole M.A., May, Annette, Duyster, Justus, Huls, Gerwin, van der Velden, Walter J.F.M., Finke, Jürgen, and Lübbert, Michael

Published
2018
Full Text
View/download PDF

9. The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Author

Hermans, Sjoerd J.F., Norden, Yvette, Versluis, Jurjen, Rijneveld, Anita W., De Weerdt, Okke, Biemond, Bart J., van de Loosdrecht, Arjan A., Van der Wagen, Lotte E., Bellido, Mar, Van Gelder, Michel, Van der Velden, Walter J.F.M., Selleslag, Dominik, van Lammeren, Danielle, van der Velden, Vincent H.J., de Wreede, Liesbeth C., Postmus, Douwe, Pignatti, Francesco, and Cornelissen, Jan J.

Published
2022
Full Text
View/download PDF

10. Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

Author

Hobo, Willemijn, Broen, Kelly, van der Velden, Walter J.F.M., Greupink-Draaisma, Annelies, Adisty, Niken, Wouters, Yannick, Kester, Michel, Fredrix, Hanny, Jansen, Joop H., van der Reijden, Bert, Falkenburg, J.H. Frederik, de Witte, Theo, Preijers, Frank, Schattenberg, Ton, Feuth, Ton, Blijlevens, Nicole M., Schaap, Nicolaas, and Dolstra, Harry

Published
2013
Full Text
View/download PDF

14. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients

Author

Plantinga, Theo S., van der Velden, Walter J.F.M., Ferwerda, Bart, van Spriel, Annemiek B., Adema, Gosse, Feuth, Ton, Donnelly, J. Peter, Brown, Gordon D., Kullberg, Bart-Jan, Blijlevens, Nicole M.A., and Netea, Mihai G.

Subjects
Genetic polymorphisms -- Research, Genetic polymorphisms -- Control, Candida -- Research, Candida -- Physiological aspects, Candidiasis -- Prevention, Hematopoietic stem cells -- Transplantation, Hematopoietic stem cells -- Usage, Hematopoietic stem cells -- Patient outcomes, Health, Health care industry
Published
2009

18. Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Author

Zeiser, Robert, Burchert, Andreas, Lengerke, Claudia, Verbeek, Mareike, Maas-Bauer, Kristina, Metzelder, Stephan, Spoerl, Silvia, Ditschkowski, Markus, Ecsedi, Matyas, Sockel, Katja, Ayuk, Francis, Salem, Ajib, Sicre de Fontbrune, Flore, Na, Il-Kang, Livius, Penter, Holtick, Udo, Wolf, Dominik, Schuler, Esther, Meyer, Everett, Apostolova, Petya, Bertz, Hartmut, Marks, Reinhard, Lübbert, Michael, Wäsch, Ralph, Scheid, Christof, Stölzel, Friedrich, Ordemann, Rainer, Bug, Gesine, Kobbe, Guido, Shah, Omid, Negrin, Robert S., Brune, Mats, Spyridonidis, Alexandros, Schmitt-Graeff, Annette, van der Velden, Walter J.F.M., Huls, Gerwin, Mielke, Stephan, Grigoleit, Goetz Ulrich, Kuball, Jurgen, Flynn, Ryan P, Ihorst, Gabriele, Du, Jing, Blazar, Bruce R., Arnold, Renate, Kröger, Nicolaus, Passweg, Jakob R., Halter, Joerg, Socié, Gérard, Beelen, Dietrich W., Peschel, Christian, Neubauer, Andreas, Finke, Jürgen, Duyster, Justus, and von Bubnoff, Nikolas

Published
2016
Full Text
View/download PDF

19. Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Author

Baron, Frederic, Efficace, Fabio, Cannella, Laura, Mandelli, Franco, Willemze, Roelof, Muus, Petra, Marie, Jean-Pierre, Ferrero, Dario, Dictus, Marlies, Fazi, Paola, La Sala, Edoardo, Bourhis, Jean-Henri, Fabbiano, Francesco, Bosi, Alberto, Sborgia, Marco, Martinelli, Giovanni, Bron, Dominique, Petti, Maria C., Halkes, Constantijn J.M., van der Velden, Walter J.F.M., Boccadoro, Mario, Amadori, Sergio, Zittoun, Robert A., and Suciu, Stefan

Published
2016
Full Text
View/download PDF

20. The incidence of acute graft-versus-host disease increases with Candida colonization depending the dectin-1 gene status

Author

van der Velden, Walter J.F.M., Plantinga, Theo S., Feuth, Ton, Donnelly, J. Peter, Netea, Mihai G., and Blijlevens, Nicole M.A.

Subjects
*DISEASE incidence, *GRAFT versus host disease, *COLONIZATION (Ecology), *ANTIFUNGAL agents, *IMMUNOLOGY, *GENETIC polymorphisms, *STEM cell transplantation
Abstract

Abstract: Dectin-1 plays an important role in antifungal immunity. The dectin-1 Y238X polymorphism, which results in decreased Th17 responses, is associated with increased Candida colonization of stem cell transplantation (SCT) recipients. In this study we found no impact of the polymorphism on the incidence of graft-versus-host disease (GvHD), or on disease-free and overall survival in these SCT recipients. However, patients from patient–donor pairs bearing the wild-type allele who where colonized with Candida had a significant increased incidence of acute GvHD compared to non-colonized patients (OR=2.6, P =0.04). The fact that this was not the case in patients from pairs with the Y238X polymorphism (OR=1.2, ns) suggests that despite increased colonization defective dectin-1 signaling might have prevented an impact of Candida colonization on the incidence of acute GvHD to occur. These are the first human data showing a role for Candida in the pathogenesis of acute GvHD. The mechanism could involve C-type lectin receptor mediated Th17 responses. [Copyright &y& Elsevier]

Published
2010
Full Text
View/download PDF

22. Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation,

Author

Hobo, Willemijn, Broen, Kelly, van der Velden, Walter J.F.M., Greupink-Draaisma, Annelies, Adisty, Niken, Wouters, Yannick, Kester, Michel G.D., Fredrix, Hanny, Jansen, Joop H., van der Reijden, Bert A., Falkenburg, J.H. Frederik, de Witte, Theo, Preijers, Frank W.M.B., Schattenberg, Anton, Feuth, Ton, Blijlevens, Nicole N.A., Schaap, Nicolaas, and Dolstra, Harry

Published
2011
Full Text
View/download PDF

24. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment.

Author

Cirovic, Branko, de Bree, L. Charlotte J., Groh, Laszlo, Blok, Bas A., Chan, Joyce, van der Velden, Walter J.F.M., Bremmers, M.E.J., van Crevel, Reinout, Händler, Kristian, Picelli, Simone, Schulte-Schrepping, Jonas, Klee, Kathrin, Oosting, Marije, Koeken, Valerie A.C.M., van Ingen, Jakko, Li, Yang, Benn, Christine S., Schultze, Joachim L., Joosten, Leo A.B., and Curtis, Nigel

Abstract

Induction of trained immunity by Bacille-Calmette-Guérin (BCG) vaccination mediates beneficial heterologous effects, but the mechanisms underlying its persistence and magnitude remain elusive. In this study, we show that BCG vaccination in healthy human volunteers induces a persistent transcriptional program connected to myeloid cell development and function within the hematopoietic stem and progenitor cell (HSPC) compartment in the bone marrow. We identify hepatic nuclear factor (HNF) family members 1a and b as crucial regulators of this transcriptional shift. These findings are corroborated by higher granulocyte numbers in BCG-vaccinated infants, HNF1 SNP variants that correlate with trained immunity, and elevated serum concentrations of the HNF1 target alpha-1 antitrypsin. Additionally, transcriptomic HSPC remodeling was epigenetically conveyed to peripheral CD14+ monocytes, displaying an activated transcriptional signature three months after BCG vaccination. Taken together, transcriptomic, epigenomic, and functional reprogramming of HSPCs and peripheral monocytes is a hallmark of BCG-induced trained immunity in humans. • Human BCG vaccination induces a persistent innate immune training of CD14+ monocytes • BCG vaccination imprints a persistent transcriptomic myeloid bias on human HSPCs • Hepatic nuclear factors are regulators of BCG-induced trained immunity in HSPCs • BCG induces persistent epigenetic changes in peripheral CD14+ monocytes Cirovic and de Bree et al. investigate the effects of BCG vaccination in humans and reveal the induction of a transcriptomic rewiring of human stem and progenitor cells toward the myeloid cell lineage, instructed by hepatic nuclear factors, resulting in epigenetic and functional changes within CD14+ peripheral monocytes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Author

Groth, Christoph, van Groningen, Lenneke F.J., Matos, Tiago R., Bremmers, Manita E., Preijers, Frank W.M.B., Dolstra, Harry, Reicherts, Christian, Schaap, Nicolaas P.M., van Hooren, Eric H.G., IntHout, Joanna, Masereeuw, Rosalinde, Netea, Mihai G., Levine, John E., Morales, George, Ferrara, James L., Blijlevens, Nicole M.A., van Oosterhout, Ypke V.J.M., Stelljes, Matthias, and van der Velden, Walter J.F.M.

Subjects
*GRAFT versus host disease, *ACUTE diseases, *CYTOTOXIC T cells, *T cell receptors, *RITUXIMAB, *ANTIBODY-toxin conjugates
Abstract

Highlights • CD3/CD7-IT therapy was effective in treating steroid-refractory acute graft-versus-host disease, with promising 6-month overall survival. • Treatment with CD3/CD7-IT proved safe and was well tolerated. • After CD3/CD7-IT therapy, immune reconstitution with a diversified repertoire occurred. ABSTRACT Effective therapies for treating patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD), particularly strategies that reduce the duration of immunosuppression following remission, are urgently needed. The investigated immunotoxin combination consists of a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT), which induces in vivo depletion of T cells and natural killer (NK) cells and suppresses T cell receptor activation. We conducted a phase I/II trial to examine the safety and efficacy of CD3/CD7-IT in 20 patients with SR-aGVHD; 17 of these patients (85%) had severe SR-aGVHD, and all 20 patients had visceral organ involvement, including 18 (90%) with gastrointestinal (GI) involvement and 5 (25%) with liver involvement. A validated 2-biomarker algorithm classified the majority of patients (11 of 20) as high risk. On day 28 after the start of CD3/CD7-IT therapy, the overall response rate was 60% (12 of 20), with 10 patients (50%) achieving a complete response. The 6-month overall survival rate was 60% (12 of 20), including 64% (7 of 11) classified as high risk by biomarkers. The 1-week course of treatment with CD3/CD7-IT caused profound but transient depletion of T cells and NK cells, followed by rapid recovery of the immune system with a diverse TCR Vβ repertoire, and preservation of Epstein-Barr virus- and cytomegalovirus-specific T cell clones. Furthermore, our results indicate that CD3/CD7-IT appeared to be safe and well tolerated, with a relatively low prevalence of manageable and reversible adverse events, primarily worsening of hypoalbuminemia, microangiopathy, and thrombocytopenia. These encouraging results suggest that CD3/CD7-IT may improve patient outcomes in patients with SR-aGVHD. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results